The Cost of Not Retesting: Human Immunodeficiency Virus Misdiagnosis in the Antiretroviral Therapy “Test-and-Offer” Era
Open Access
- 24 April 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 65 (3) , 522-525
Abstract
We compared estimated costs of retesting human immunodeficiency virus (HIV)-positive persons before antiretroviral therapy (ART) initiation to the costs of ART provision to misdiagnosed HIV-negative persons. Savings from averted unnecessary ART costs were greater than retesting costs within 1 year using assumptions representative of HIV testing performance in programmatic settings. Countries should implement re-testing before ART initiation.Keywords
Funding Information
- Bill and Melinda Gates Foundation
- Wellcome Trust
This publication has 6 references indexed in Scilit:
- Optimum resource allocation to reduce HIV incidence across sub-Saharan Africa: a mathematical modelling studyThe Lancet HIV, 2016
- Is Zimbabwe ready to transition from anonymous unlinked sero-surveillance to using prevention of mother to child transmission of HIV (PMTCT) program data for HIV surveillance?: results of PMTCT utility study, 2012BMC Infectious Diseases, 2016
- Systematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in sub-Saharan AfricaNature, 2015
- Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-EffectivenessPLOS ONE, 2014
- False Positive HIV Diagnoses in Resource Limited Settings: Operational Lessons Learned for HIV ProgrammesPLOS ONE, 2013
- The Evaluation of a Rapid In Situ HIV Confirmation Test in a Programme with a High Failure Rate of the WHO HIV Two-Test Diagnostic AlgorithmPLOS ONE, 2009